375 related articles for article (PubMed ID: 31264190)
1. Pulmonary and Regional Deposition of Nebulized and Dry Powder Aerosols in Ferrets.
Kuehl PJ; Chand R; McDonald JD; Hava DL; DeHaan WH
AAPS PharmSciTech; 2019 Jul; 20(6):242. PubMed ID: 31264190
[TBL] [Abstract][Full Text] [Related]
2. Dry powder aerosol delivery systems: current and future research directions.
Chan HK
J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
[TBL] [Abstract][Full Text] [Related]
3. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
4. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers.
Glover W; Chan HK; Eberl S; Daviskas E; Verschuer J
Int J Pharm; 2008 Feb; 349(1-2):314-22. PubMed ID: 17904774
[TBL] [Abstract][Full Text] [Related]
5. The role of particle properties in pharmaceutical powder inhalation formulations.
Chew NY; Chan HK
J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary drug delivery by powder aerosols.
Yang MY; Chan JG; Chan HK
J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
[TBL] [Abstract][Full Text] [Related]
7. Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition.
Liao Q; Yip L; Chow MYT; Chow SF; Chan HK; Kwok PCL; Lam JKW
Int J Pharm; 2019 Apr; 560():144-154. PubMed ID: 30731259
[TBL] [Abstract][Full Text] [Related]
8. Regional particle size dependent deposition of inhaled aerosols in rats and mice.
Kuehl PJ; Anderson TL; Candelaria G; Gershman B; Harlin K; Hesterman JY; Holmes T; Hoppin J; Lackas C; Norenberg JP; Yu H; McDonald JD
Inhal Toxicol; 2012 Jan; 24(1):27-35. PubMed ID: 22145784
[TBL] [Abstract][Full Text] [Related]
9. Development of dry powder inhalers.
Chougule MB; Padhi BK; Jinturkar KA; Misra A
Recent Pat Drug Deliv Formul; 2007; 1(1):11-21. PubMed ID: 19075871
[TBL] [Abstract][Full Text] [Related]
10. Adapting the Aerogen Mesh Nebulizer for Dried Aerosol Exposures Using the PreciseInhale Platform.
Gerde P; Nowenwik M; Sjöberg CO; Selg E
J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):116-126. PubMed ID: 31613690
[No Abstract] [Full Text] [Related]
11. Model Calculations of Regional Deposition and Disposition for Single Doses of Inhaled Liposomal and Dry Powder Ciprofloxacin.
Martin AR; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):49-60. PubMed ID: 28708440
[TBL] [Abstract][Full Text] [Related]
12. Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion.
Sangwan S; Agosti JM; Bauer LA; Otulana BA; Morishige RJ; Cipolla DC; Blanchard JD; Smaldone GC
J Aerosol Med; 2001; 14(2):185-95. PubMed ID: 11681650
[TBL] [Abstract][Full Text] [Related]
13. Dose delivery late in the breath can increase dry powder aerosol penetration into the lungs.
Bondesson E; Bengtsson T; Borgström L; Nilsson LE; Norrgren K; Olsson B; Svensson M; Wollmer P
J Aerosol Med; 2005; 18(1):23-33. PubMed ID: 15741771
[TBL] [Abstract][Full Text] [Related]
14. Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.
Wilson EM; Luft JC; DeSimone JM
Pharm Res; 2018 Aug; 35(10):195. PubMed ID: 30141117
[TBL] [Abstract][Full Text] [Related]
15. Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats.
Carvalho SR; Watts AB; Peters JI; Liu S; Hengsawas S; Escotet-Espinoza MS; Williams RO
Eur J Pharm Biopharm; 2014 Sep; 88(1):136-47. PubMed ID: 24859653
[TBL] [Abstract][Full Text] [Related]
16. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
Bur M; Huwer H; Muys L; Lehr CM
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):119-27. PubMed ID: 20073555
[TBL] [Abstract][Full Text] [Related]
17. Formulation and evaluation of insulin dry powder for inhalation.
Mahesh Kumar T; Misra A
Drug Dev Ind Pharm; 2006 Jul; 32(6):677-86. PubMed ID: 16885123
[TBL] [Abstract][Full Text] [Related]
18. Investigation of Lung Pharmacokinetic of the Novel PDE4 Inhibitor CHF6001 in Preclinical Models: Evaluation of the PreciseInhale Technology.
Fioni A; Selg E; Cenacchi V; Acevedo F; Brogin G; Gerde P; Puccini P
J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):61-70. PubMed ID: 28768120
[TBL] [Abstract][Full Text] [Related]
19. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
[TBL] [Abstract][Full Text] [Related]
20. Multicomponent aerosol particle deposition in a realistic cast of the human upper respiratory tract.
Nordlund M; Belka M; Kuczaj AK; Lizal F; Jedelsky J; Elcner J; Jicha M; Sauser Y; Le Bouhellec S; Cosandey S; Majeed S; Vuillaume G; Peitsch MC; Hoeng J
Inhal Toxicol; 2017 Feb; 29(3):113-125. PubMed ID: 28470142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
